Deception On Both Sides: The FDA vs. Pro-Kratom Advocates


The FDA released a statement warning people about Mitragyna speciosa (Kratom) on November 14, 2017. Although that statement didn’t confirm the government is going to pursue a ban on the plant, it’s not a very hopeful message. Much like the DEA, the FDA highlighted poisonings and fatalities associated with kratom and kratom-containing products. But it’s likely most of those involved polydrug exposure. There’s little evidence kratom by itself has a high overdose death potential.

We’re still waiting to see what the FDA recommends to the DEA. That recommendation could push the government towards prohibiting the substance, just as federal authorities tried to do through emergency scheduling in 2016.

Along with discussing the misleading nature of the FDA’s statement, I discuss misleading statements from advocates who oppose a ban. Sadly, it appears a lot of people are advocating against prohibition using arguments that spread false ideas about the substance.


Aggarwal, G., Robertson, E., McKinlay, J., & Walter, E. (2017). Death from Kratom toxicity and the possible role of intralipid. Journal of the Intensive Care Society, 0(0), 175114371771265.

Anwar, M., Law, R., & Schier, J. (2016). Notes from the Field: Kratom (Mitragyna speciosa) Exposures Reported to Poison Centers – United States, 2010-2015. MMWR. Morbidity and Mortality Weekly Report, 65(29), 748–749.

Arnautovic, J., Souther, B., Tereziu, S., & Weerakoon, N. (2016). Kratom-induced alveolar hemorrhage. Critical Care Medicine, 44(12), 553.

Bunnag, A., Meyen, R., & Fernando, I. (2017). Kratom ( Mitragyna speciosa ) Use in a Veteran With Chronic Pain. The American Journal of Psychiatry Residents’ Journal, (3), 13–15.

Castillo, A., Payne, J. D., & Nugent, K. (2017). Posterior reversible leukoencephalopathy syndrome after kratom ingestion. Proceedings (Baylor University. Medical Center), 30(3), 355–357. Retrieved from

Chang-Chien, G. C., Odonkor, C. A., & Amorapanth, P. (2017). Is Kratom the New “Legal High” on the Block?: The Case of an Emerging Opioid Receptor Agonist with Substance Abuse Potential. Pain Physician, 20(1), E195–E198. Retrieved from

Cinosi, E., Martinotti, G., Simonato, P., Singh, D., Demetrovics, Z., Roman-Urrestarazu, A., … Corazza, O. (2015). Following “the Roots” of Kratom (Mitragyna speciosa): The Evolution of an Enhancer from a Traditional Use to Increase Work and Productivity in Southeast Asia to a Recreational Psychoactive Drug in Western Countries. BioMed Research International, 2015.

Cumpston, K. L., Carter, M., & Wills, B. K. (2017). Clinical outcomes after Kratom exposures: A poison center case series. The American Journal of Emergency Medicine, 3, 2–3.

DEA. (n.d.). DEA Resource Guide – 2017.

Diep, J., Chin, D. T., Gupta, S., Syed, F., Xiong, M., & Cheng, J. (2017). Kratom, an Emerging Drug of Abuse. A & A Case Reports, XXX(Xxx), 1.

Domingo, O., Roider, G., Stöver, A., Graw, M., Musshoff, F., Sachs, H., & Bicker, W. (2017). Mitragynine concentrations in two fatalities. Forensic Science International, 271, e1–e7.

Dorman, C., Wong, M., & Khan, A. (2015). Cholestatic hepatitis from prolonged kratom use: A case report. Hepatology, 61(3), 1086–1087.

Drago, J. Z., Lane, B., Kochav, J., & Chabner, B. (2017). The Harm in Kratom. The Oncologist, 22(8), 1010–1011.

Forrester, M. B. (2017). Texas Bull Nettle (Cnidoscolus texanus) Exposures Reported to Texas Poison Centers. Wilderness and Environmental Medicine, 28(2), 79–83.

Griffin, O. H., & Webb, M. E. (2017). The Scheduling of Kratom and Selective Use of Data. Journal of Psychoactive Drugs, 1072(September), 1–7.

Harizal, S. N., Mansor, S. M., Hasnan, J., Tharakan, J. K. J., & Abdullah, J. (2010). Acute toxicity study of the standardized methanolic extract of Mitragyna speciosa Korth in Rodent. Journal of Ethnopharmacology, 131(2), 404–409.

Hassan, Z., Muzaimi, M., Navaratnam, V., Yusoff, N. H. M., Suhaimi, F. W., Vadivelu, R., … Müller, C. P. (2013). From Kratom to mitragynine and its derivatives: Physiological and behavioural effects related to use, abuse, and addiction. Neuroscience & Biobehavioral Reviews, 37(2), 138–151.

Houghton, P. (1989). Alkaloids from mitragyna speciosa. Phytochemistry, 40(3), 497–501.

Ilmie, M. U., Jaafar, H., Mansor, S. M., & Abdullah, J. M. (2015). Subchronic toxicity study of standardized methanolic extract of mitragyna speciosa korth in sprague-dawley rats. Frontiers in Neuroscience, 9(MAY), 1–6.

Jamil, M. F. A., Subki, M. F. M., Lan, T. M., Majid, M. I. A., & Adenan, M. I. (2013). The effect of mitragynine on cAMP formation and mRNA expression of mu-opioid receptors mediated by chronic morphine treatment in SK-N-SH neuroblastoma cell. Journal of Ethnopharmacology, 148(1), 135–143.

Kapp, F. G., Maurer, H. H., Auw??rter, V., Winkelmann, M., & Hermanns-Clausen, M. (2011). Intrahepatic Cholestasis Following Abuse of Powdered Kratom (Mitragyna speciosa). Journal of Medical Toxicology, 7(3), 227–231.

Karinen, R., Fosen, J. T., Rogde, S., & Vindenes, V. (2014). An accidental poisoning with mitragynine. Forensic Science International, 245, e29–e32.

Kruegel, A. C., Gassaway, M. M., Kapoor, A., Váradi, A., Majumdar, S., Filizola, M., … Sames, D. (2016). Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators. Journal of the American Chemical Society, 138(21), 6754–6764.

Kruegel, A. C., & Grundmann, O. (2017). The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse. Neuropharmacology. Elsevier Ltd.

Lanier, R. K., Fant, R. V., Cone, E., & Henningfield, J. (2017). Assessment of the abuse potential and benefits of kratom and its mitragynine alkaloids: Implications for regulation. Drug and Alcohol Dependence, 171(2017), e114.

Lydecker, A. G., Sharma, A., McCurdy, C. R., Avery, B. A., Babu, K. M., & Boyer, E. W. (2016). Suspected Adulteration of Commercial Kratom Products with 7-Hydroxymitragynine. Journal of Medical Toxicology, 12(4), 341–349.

Lydecker, A. G., Zuckkerman, M. D., Hack, J. B., Becker, B., Cherkes, J. K., Boyer, E. W., & Babu, K. M. (2017). Intravenous Kratom Use in aPatient with Opioid Dependence. Journal of Toxicology and Pharmacology, 1(1).

Madariaga-Mazón, A., Marmolejo-Valencia, A. F., Li, Y., Toll, L., Houghten, R. A., & Martinez-Mayorga, K. (2017). Mu-Opioid receptor biased ligands: A safer and painless discovery of analgesics? Drug Discovery Today, 22(11), 1719–1729.

McIntyre, I. M., Trochta, A., Stolberg, S., & Campman, S. C. (2015). Mitragynine “Kratom” related fatality: A case report with postmortem concentrations. Journal of Analytical Toxicology, 39(2), 152–155.

Neerman, M. F., Frost, R. E., & Deking, J. (2013). A Drug Fatality Involving Kratom. Journal of Forensic Sciences, 58(SUPPL. 1), 278–279.

Parthasarathy, S., Ramanathan, S., Ismail, S., Adenan, M. I., Mansor, S. M., & Murugaiyah, V. (2010). Determination of mitragynine in plasma with solid-phase extraction and rapid HPLC-UV analysis, and its application to a pharmacokinetic study in rat. Analytical and Bioanalytical Chemistry, 397(5), 2023–2030.

Prozialeck, W. C. (2016). Update on the Pharmacology and Legal Status of Kratom. The Journal of the American Osteopathic Association, 116(12), 802.

Prozialeck, W. C., Jivan, J. K., & Andurkar, S. V. (2012). Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. The Journal of the American Osteopathic Association, 112(12), 792–9.

Shellard, E., Houghton, P., & Resha, M. (1978). The Mitragyna Species of Asia. Planta Medica, 34(7), 253–263.

Singh, D., Müller, C. P., & Vicknasingam, B. K. (2014). Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. Drug and Alcohol Dependence, 139, 132–137.

Singh, D., Narayanan, S., & Vicknasingam, B. (2016). Traditional and non-traditional uses of Mitragynine (Kratom): A survey of the literature. Brain Research Bulletin, 126, 41–46.

Siuda, E. R., Carr, R., Rominger, D. H., & Violin, J. D. (2017). Biased mu-opioid receptor ligands: a promising new generation of pain therapeutics. Current Opinion in Pharmacology, 32, 77–84.

Smith, K. E., & Lawson, T. (2017). Prevalence and motivations for kratom use in a sample of substance users enrolled in a residential treatment program. Drug and Alcohol Dependence, 180(July), 340–348.

Suhaimi, F. W., Yusoff, N. H. M., Hassan, R., Mansor, S. M., Navaratnam, V., Müller, C. P., & Hassan, Z. (2016). Neurobiology of Kratom and its main alkaloid mitragynine. Brain Research Bulletin, 126, 29–40.

Swogger, M. T., Hart, E., Erowid, F., Erowid, E., Trabold, N., Yee, K., … Walsh, Z. (2015). Experiences of Kratom Users: A Qualitative Analysis. Journal of Psychoactive Drugs, 47(5), 360–367.

Takayama, H. (2004). Chemistry and pharmacology of analgesic indole alkaloids from the rubiaceous plant, Mitragyna speciosa. Chemical & Pharmaceutical Bulletin, 52(8), 916–928.

Trakulsrichai, S., Tongpo, A., Sriapha, C., Wongvisawakorn, S., Rittilert, P., Kaojarern, S., & Wananukul, W. (2013). Kratom Abuse in Ramathibodi Poison Center, Thailand: A Five-Year Experience. Journal of Psychoactive Drugs, 45(5), 404–408.

Váradi, A., Marrone, G. F., Palmer, T. C., Narayan, A., Szabó, M. R., Le Rouzic, V., … Majumdar, S. (2016). Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2. Journal of Medicinal Chemistry, 59(18), 8381–8397.

Voelker, R. (2016). Kratom Products Seized. Jama-Journal of the American Medical Association, 316(11), 1142.

Warner, M. L., Kaufman, N. C., & Grundmann, O. (2016). The pharmacology and toxicology of kratom: from traditional herb to drug of abuse. International Journal of Legal Medicine, 130(1), 127–138.

Yusoff, N. H. M., Mansor, S. M., Müller, C. P., & Hassan, Z. (2017). Opioid receptors mediate the acquisition, but not the expression of mitragynine-induced conditioned place preference in rats. Behavioural Brain Research, 332(March), 1–6.

Yusoff, N. H. M., Suhaimi, F. W., Vadivelu, R. K., Hassan, Z., R??mler, A., Rotter, A., … M??ller, C. P. (2016). Abuse potential and adverse cognitive effects of mitragynine (kratom). Addiction Biology, 21(1), 98–110.

  • DillyDallyLove55

    Thanks. This information is needed! It has helped me with my depression and if the FDA should be fighting against anything it should be alcohol! Just saw a video and a drunk idiot got her baby split in half! Ban alcohol, that kills! This substance helps me and many others with mental health issues… I am glad Kratom got me away from trying to treat my “issues” with alcohol almost as soon as I started drinking the booze. Thanks again for the info! ☀️